In vitro activities of the new macrolides clarithromycin, previously designated A-56268 , and A-63075 and of the aryl-fluoroquinolones difloxacin (A-56619) and temafloxacin (A-62254) against 14 strains of Mycoplasma pneumoniae, 20 strains of Mycoplasma hominis, and 28 strains of Ureaplasma urealyticum were compared with that of erythromycin. All The number of organisms added was verified by serial tenfold dilutions of the suspension used to inoculate the assay plates (0.1 ml/0.9 ml of broth). These were incubated, and CCU per milliliter was determined to ensure that an adequate (103 CCU/ml) but not excessive (>105 CCU/ml) amount was actually inoculated into the test system. Controls included in every microdilution plate assay for each strain and drug tested were (i) a broth control without 1500 ANTIMICROBIAL
Mycoplasmas are gaining increasing attention as significant human pathogens. Mycoplasma pneumoniae is an important cause of tracheobronchitis in school-aged children and accounts for up to 20% of all pneumonia cases in the general population (4) . Mycoplasma hominis and Ureaplasma urealyticum are responsible for numerous pathologic conditions of the urogenital tract as well as other organ systems, particularly in immunosuppressed persons and newborn infants (5) . Antibiotic resistance to currently available drugs in many strains of genital mycoplasmas intensifies the need to evaluate new antimicrobial agents to treat infections caused by these organisms (8, 12, 16) .
In this paper, we describe the in vitro potencies of the new synthetic macrolides clarithromycin and A-63075 and of the quinolones temafloxacin and difloxacin against M. pneumoniae, M. hominis, and U. urealyticum. Their The number of organisms added was verified by serial tenfold dilutions of the suspension used to inoculate the assay plates (0.1 ml/0.9 ml of broth). These were incubated, and CCU per milliliter was determined to ensure that an adequate (103 CCU/ml) but not excessive (>105 CCU/ml) amount was actually inoculated into the test system. Controls included in every microdilution plate assay for each strain and drug tested were (i) a broth control without 16 p.g/ml); these MICs were lower by one or more dilutions for each of the remaining 23 strains except 1, for which the values were equivalent. Among these 23 strains, final MICs of clarithromycin ranged from 0.031 to 4 ,ug/ml, while those of erythromycin were 0.063 to 32 pug/ml. Initial MICs of A-63075 for this group ranged from 0.5 to 128 ,ug/ml, and final MICs were 4 to 128 ,ug/ml. For two strains, the initial MIC of A-63075 was 1 dilution lower than that of erythromycin, for 2 others the initial MICs were equivalent, while for the remainder, MICs of A-63075 were 1 to several dilutions higher.
For only one U. urealyticum strain, a respiratory tract isolate from a newborn infant, were initial and final MICs higher than 256 ,ug/ml for both quinolones. This particular organism was susceptible to both erythromycin and clarithromycin (with initial MICs of 0.125 and 0.5 ,.g/ml, respectively). For the 5 Ureaplasma strains for which macrolide MICs were >256 ,.g/ml, the corresponding initial MICs of temafloxacin ranged from 1 to 4 ,ug/ml and those of difloxacin were 2 to 8 jig/ml. For most U. urealyticum strains, the final MIC of the quinolones exceeded the initial MIC by 1 to 3 dilutions, as was the case with M. hominis.
DISCUSSION
Erythromycin resistance in M. pneumoniae has not been described. M. hominis, however, is always resistant, and resistant strains of U. urealyticum are now being reported with increasing frequency (8, 12, 16) .
Activity of the synthetic macrolide clarithromycin is comparable or superior to that of erythromycin against most bacteria (6), but its effect on mycoplasmas has not previously been described. Clarithromycin is better absorbed and has a higher peak level in serum and a half-life which is twice that of erythromycin (6) . Approximately 10 times the concentration in serum occurs in lung tissue (P. B. Fernandes, Antibiot. Newsl. 4:25-35, 1987) .
Difloxacin and temafloxacin are investigational quinolones with broad spectrums of activity (7, 15) . Studies of difloxacin VOL. 32, 1988 in mice indicate virtually complete absorption after oral administration, with a half-life of over 10 h (7) .
Limited information concerning the activities of some quinolones against mycoplasmas is available. Osada and Ogawa (9) tested ofloxacin against M. pneumoniae and M.
hominis and found its activity comparable with that of tetracycline but inferior to that of erythromycin against M. pneumoniae. Ridgway et al. (11) found ciprofloxacin activity equivalent to that of oxytetracycline against a small number of M. hominis and U. urealyticum strains. Aznar et al. (1) tested ofloxacin and other quinolones against 32 strains of U. urealyticum and found that 90% were susceptible at <8 ,ug/ ml. Ofloxacin was superior to norfloxacin, ciprofloxacin, and enoxacin but inferior to doxycycline.
The present study shows that clarithromycin as well as A-63075 inhibited the growth of M. pneumoniae at low concentrations, similar to erythromycin. Because of the broad spectrum of activity and improved pharmacologic properties, the new macrolides may prove to be important drugs for M. pneumoniae infections. M. pneumoniae was also susceptible to the quinolones at relatively low concentrations; however, neither quinolone was as effective as the macrolides.
Resistance of all 20 strains of M. hominis to the three macrolides was not unexpected (6) . Both quinolones were more active than the macrolides against M. hominis, although their potential therapeutic significance will depend on results of additional pharmacokinetic and clinical experiments with humans. MICs of the quinolones against U. urealyticum suggest a similar situation for that organism. The activities of the quinolones against all three species were remarkably similar.
The five highly erythromycin-resistant strains of U. urealyticum were equally resistant to clarithromycin and A-63075. However, the lower MICs of clarithromycin in comparison with erythromycin in almost every other U. urealyticum strain tested suggest a potential use for this drug which should be further evaluated.
Macrolides are less active at pH 6.5 than at pH 7.2 to 7.3, while MICs of difloxacin are similar at these pH values (6, 15) . The low pH of the test system for U. urealyticum was necessary for the interpretation of the MIC and optimal growth of the organism (14) . Thus, the actual MICs of the macrolides at physiologic pH might be lower.
Many infections due to mycoplasmas or ureaplasmas are not septicemias, and therefore achievable drug levels in serum may not accurately reflect concentrations at the actual site of infection. This may account for some disagreement between observed levels of clinical resistance and outcome of therapy predicted from MICs or levels in serum. Depending on the nature and site of infection, local pH, or other factors, levels in serum in excess of the MIC may be necessary for a bacteriologic cure. Pharmacokinetic studies and clinical trials of the new macrolides and quinolones with humans with mycoplasmal or ureaplasmal infections are indicated.
